GlassScriptPhysician profile
Fiona Mienko
NPI 1023495066
$14,779.98
in general payments reported to CMS, 2019-2025
76 companies · $6,135 in 2025
The $6,135 reported for 2025 was more than what 76% of Medical Oncology providers received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $34.58 · 2022: $328 · 2023: $2,679 · 2024: $5,604 · 2025: $6,135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Long Term Medical Supply Or Device Loan: $2,348 · Education: $33.42.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $12,035.99 |
| Long Term Medical Supply Or Device Loan | $2,348.13 |
| Education | $33.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,119.22 | 2023-2025 | |
| Janssen Biotech, INC. | $1,062.95 | 2023-2025 | Talvey, Tecvayli, Rybrevant |
| Exelixis INC. | $709.38 | 2023-2025 | Cabometyx |
| Pfizer INC. | $692.56 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $482.48 | 2022-2025 | Calquence, Lynparza, Enhertu |
| Celgene Corporation | $418.36 | 2023-2025 | Breyanzi, Pomalyst, Reblozyl |
| Merck Sharp & Dohme LLC | $372.96 | 2022-2025 | Keytruda, Keytruda Qlex, Lynparza |
| Daiichi Sankyo INC. | $369.51 | 2023-2025 | Enhertu, Datroway, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $345.51 | 2022-2025 | Iclusig, Fruzaqla, Alunbrig |
| Incyte Corporation | $301.65 | 2022-2025 | Jakafi, Monjuvi, Zynyz |
| Abbvie INC. | $287.03 | 2024-2025 | |
| Tersera Therapeutics LLC | $287.00 | 2023-2025 | Zoladex, Xermelo, Quzyttir |
| Glaxosmithkline, LLC. | $249.94 | 2022-2025 | Ojjaara, Jemperli, Zejula |
| Genentech USA, INC. | $241.63 | 2023-2025 | Polivy, Tecentriq, Lunsumio |
| E.R. Squibb & Sons, L.L.C. | $233.13 | 2021-2025 | Opdivo |
Show all 76 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $227.90 | 2023-2025 | |
| Astellas Pharma US INC | $226.07 | 2023-2025 | Padcev, Vyloy, Xtandi |
| Regeneron Healthcare Solutions, INC. | $223.28 | 2023-2025 | Libtayo, Lynozyfic |
| Eisai INC. | $215.74 | 2023-2025 | |
| Beone Medicines USA, INC. | $204.16 | 2025 | Brukinsa, Tevimbra |
| Alexion Pharmaceuticals, INC. | $191.17 | 2022-2025 | Ultomiris |
| Servier Pharmaceuticals LLC | $179.77 | 2023-2025 | |
| Genmab U.S., INC. | $174.35 | 2023-2025 | Epkinly |
| Emd Serono, INC. | $168.30 | 2023-2025 | Tepmetko |
| Ipsen Biopharmaceuticals, INC | $166.55 | 2023-2025 | Onivyde, Somatuline Depot, Tazverik |
| Gilead Sciences, INC. | $166.09 | 2023-2025 | Trodelvy |
| Array Biopharma INC | $153.73 | 2023-2025 | Braftovi, Lorbrena, Mektovi |
| Sobi, INC | $153.67 | 2024-2025 | |
| Taiho Oncology, INC. | $149.48 | 2023-2025 | |
| Beigene USA, INC. | $144.93 | 2023-2025 | Brukinsa, Tevimbra |
| Deciphera Pharmaceuticals INC. | $142.09 | 2024-2025 | Qinlock, Romvimza, Tgct |
| Amgen INC. | $136.61 | 2022-2023 | Lumakras, Kyprolis |
| Karyopharm Therapeutics INC. | $127.65 | 2024-2025 | Xpovio |
| Pharmaessentia USA Corporation | $124.56 | 2023-2025 | Besremi |
| Acrotech Biopharma INC. | $116.99 | 2023-2025 | Beleodaq |
| Spectrum Pharmaceuticals INC. | $115.66 | 2023-2025 | Rolvedon |
| Coherus Oncology, INC. | $109.75 | 2023-2025 | Loqtorzi, Udenyca |
| Pharmacosmos Therapeutics INC. | $100.53 | 2023-2025 | Monoferric |
| Agios Pharmaceuticals, INC. | $95.70 | 2023-2025 | Pyrukynd |
| Adaptive Biotechnologies Corporation | $89.84 | 2024-2025 | Clonoseq |
| Kite Pharma, INC. | $88.55 | 2023-2025 | Yescarta |
| Blueprint Medicines Corporation | $84.02 | 2023-2024 | Ayvakit |
| Caris Mpi, INC. | $83.86 | 2025 | Mi Cancer Seek |
| Mirati Therapeutics, INC. | $78.26 | 2023 | Krazati |
| Bayer Healthcare Pharmaceuticals INC. | $78.06 | 2023-2025 | |
| Stemline Therapeutics INC. | $74.89 | 2023-2025 | Orserdu, Elzonris |
| Amneal Pharmaceuticals LLC | $74.24 | 2023-2024 | Avastin |
| Janssen Pharmaceuticals, INC | $72.56 | 2023-2024 | Xarelto |
| Adc Therapeutics America, INC. | $71.40 | 2023-2025 | |
| Novocure INC. | $69.95 | 2024-2025 | Optune, Optune Lua (Novottf-200t) |
| Accord Healthcare, INC. | $68.54 | 2025 | |
| Apellis Pharmaceuticals, INC. | $66.88 | 2023-2024 | Empaveli |
| Azurity Pharmaceuticals, INC. | $57.92 | 2024-2025 | Danziten, Vivimusta |
| Alnylam Pharmaceuticals INC. | $56.24 | 2023-2025 | Givlaari |
| Puma Biotechnology, INC. | $55.88 | 2023-2025 | |
| Menarini Silicon Biosystems, INC. | $48.45 | 2025 | |
| Fennec Pharmaceuticals, INC. | $45.89 | 2025 | Fyarro |
| Rigel Pharmaceuticals, INC. | $45.32 | 2024-2025 | Rezlidhia, Tavalisse, Gavreto |
| Seagen INC. | $44.99 | 2023 | Tukysa, Adcetris |
| Pharmacyclics LLC, An Abbvie Company | $42.63 | 2023 | Imbruvica |
| Aveo Pharmaceuticals, INC. | $35.61 | 2024 | |
| Syndax Pharmaceuticals, INC. | $32.51 | 2025 | |
| Recordati_rare_diseases_inc. | $31.62 | 2025 | Sylvant |
| Fresenius Kabi USA, LLC | $31.23 | 2024 | Stimufend |
| Sun Pharmaceutical Industries INC. | $30.42 | 2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.27 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $26.87 | 2024 | Sancuso |
| Tempus Ai, INC | $25.97 | 2024 | Xt Cdx |
| Biocon Biologics INC | $24.16 | 2025 | Ogivri |
| Immunocore Limited | $20.27 | 2024 | Kimmtrak |
| Myriad Genetic Laboratories, INC. | $20.15 | 2024 | Myrisk |
| Cycle Pharmaceuticals INC | $20.00 | 2025 | Phyrago |
| Celltrion USA INC. | $18.92 | 2023 | Vegzelma |
| Invivyd INC | $16.60 | 2025 | Pemgarda |
| Secura Bio, INC. | $14.63 | 2024 | Copiktra |
| Cti Biopharma Corp. | $14.34 | 2023 | Vonjo |
Drugs and devices associated with these payments
Kisqali $2,441Cabometyx $709Epkinly $376Keytruda $311Enhertu $292Talvey $256Tecvayli $245Rybrevant $218Lenvima $216Imbruvica $215Elrexfio $214Padcev $211Brukinsa $209Darzalex $205Libtayo $197Jakafi $194Calquence $194Adcetris $186Carvykti $179Ultomiris $176Braftovi $174Opdivo $160Iclusig $159Lorbrena $155Mektovi $154Sarclisa $152Breyanzi $150Lonsurf $149Inqovi $149Zoladex $146Erleada $146Vonjo $145Trodelvy $145Bosulif $144Qinlock $142Tevimbra $140Pluvicto $135Polivy $132Tukysa $128Tibsovo $128Xpovio $128Besremi $125Inlyta $123Lynparza $122Ibrance $121Beleodaq $117Ojjaara $116Rolvedon $116Somatuline Depot $115Onivyde $115Fabhalta $115Monjuvi $113Pomalyst $111Udenyca $110Tecentriq $109Lunsumio $107Columvi $107Lutathera $101Monoferric $101Reblozyl $99.32Xermelo $97.50Jemperli $97.01Pyrukynd $95.70Clonoseq $89.84Yescarta $88.55Elahere $85.45Ayvakit $84.02Mi Cancer Seek $83.86Krazati $78.26Stivarga $78.06Vitrakvi $78.06Zynyz $75.45Avastin $74.24Zejula $74.19Xarelto $72.56Xtandi $71.45Vyloy $68.64Camcevi $68.54Empaveli $66.88Akeega $60.58Orserdu $59.32Opdualag $58.57Fruzaqla $58.09Givlaari $56.24Nubeqa $54.21Optune $53.36Tazverik $51.46Alunbrig $50.63Jevtana $49.99Cellsearch $48.45Keytruda Qlex $48.42Romvimza $47.58Fyarro $45.89Lumakras $45.41Tavalisse $45.32Rezlidhia $45.32Talzenna $43.84Datroway $43.69Quzyttir $43.26Loqtorzi $39.97
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fiona Mienko listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.